Eli Lilly and Company (LLY: NYE) is due to release its fourth-quarter earnings report this week. As investors eagerly await the update, industry experts offer their insights on what to expect from the company’s financial performance.
Eli Lilly’s Growth Prospects: J.P. Morgan Analysis Reveals
Leading analyst Chris Schott from J.P. Morgan has underscored growth prospects for Eli Lilly deriving from the success of Mounjaro and the potential of donanemab, a pioneering treatment set for launch in 2025. Schott’s estimate for fourth-quarter revenue is $8.97 billion, attributing significant revenue contribution to Mounjaro. Nonetheless, Zepbound sales are predicted to be moderate.
Looking to the future, Eli Lilly’s revenue growth for 2024 is projected by Schott at 16% year-over-year with the company’s incretin franchise forecasted to achieve $50 billion by 2030.
Stock Target Advisor’s Analysis on Eli Lilly:
Stock Target Advisor maintains a ‘Hold’ stance on Eli Lilly’s stock with a target price of 0 and envisions no price change over a 12-month period. However, the average analyst target price for Eli Lilly over the next year stands at $631.37 with a consensus rating of ‘Strong Buy.’ When it comes to Stock Target Advisor’s analysis, the view is Neutral, backed by 9 positive signals against 10 negative signals.
The company’s stock price has witnessed a surge of +28.40% over the preceding week, +53.15% over the last month, and +96.90% over the past year. These developments denote superior risk-adjusted returns and positive cash flow for Eli Lilly.
The Drug Manufacturers – General sector, inclusive of Eli Lilly, has been rated as ‘Neutral’ by Stock Target Advisor with average returns of -1.14% spanning a month.
Conclusion:
Eli Lilly’s forthcoming earnings report carries the potential to steer the company’s trajectory in 2024. Investors are encouraged to closely keep tabs on the company’s financial performance and the resulting impact of key products on its revenue and profitability.
